Sirtex hits milestone in China for yttrium-90 microspheres

By staff writers

August 31, 2020 -- Radiation oncology firm Sirtex Medical said it has crossed a milestone on its path to apply for drug registration for its SIR-Spheres yttrium-90 microspheres for treating liver cancer.

Sirtext and its partner China Grand Pharmaceutical said that they have received approval from the National Medical Products Administration in China to file a new drug application (NDA) in the country.

Receiving final approval of the NDA will enable Sirtex to enter the Chinese market, according to the firm.

SIR-Spheres yttrium-90 microspheres are used to treat patients with liver cancer, Sirtex said.

Copyright © 2020

To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking